GSK3 inhibitors: Development and therapeutic potential

被引：681

作者：

Cohen, P ^{[1
]}

Goedert, M

机构：

[1] Univ Dundee, Sch Life Sci, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland

[2] MRC, Mol Biol Lab, Cambridge CB2 2QH, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2004年 / 3卷 / 06期

关键词：

D O I：

10.1038/nrd1415

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metabolism. In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.

引用

页码：479 / 487

页数：9

共 87 条

[1]

Allen B, 2002, J NEUROSCI, V22, P9340

[2] A cell biological perspective on Alzheimer's disease [J].

Annaert, W ;

De Strooper, B .

ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, 2002, 18 :25-51

[3]

Aplin AE, 1996, J NEUROCHEM, V67, P699

[4] Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B [J].

Bae, SS ;

Cho, H ;

Mu, J ;

Birnbaum, MJ .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (49) :49530-49536

[5] The specificities of protein kinase inhibitors: an update [J].

Bain, J ;

McLauchlan, H ;

Elliott, M ;

Cohen, P .

BIOCHEMICAL JOURNAL, 2003, 371 :199-204

[6] Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418 [J].

Bhat, R ;

Xue, YF ;

Berg, S ;

Hellberg, S ;

Ormö, M ;

Nilsson, Y ;

Radesäter, AC ;

Jerning, E ;

Markgren, PO ;

Borgegård, T ;

Nylöf, M ;

Giménez-Cassina, A ;

Hernández, F ;

Lucas, JJ ;

Díaz-Nido, J ;

Avila, J .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (46) :45937-45945

[7] LITHIUM SALTS IN THE TREATMENT OF PSYCHOTIC EXCITEMENT [J].

CADE, JFJ .

MEDICAL JOURNAL OF AUSTRALIA, 1949, 2 (10) :349-352

[8] Glycogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation [J].

Carmichael, J ;

Sugars, KL ;

Bao, YP ;

Rubinsztein, DC .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (37) :33791-33798

[9]

CHENG K, 1983, MOL CELL BIOCHEM, V56, P183

[10] Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (falfa) rats [J].

Cline, GW ;

Johnson, K ;

Regittnig, W ;

Perret, P ;

Tozzo, E ;

Xiao, L ;

Damico, C ;

Shulman, GI .

DIABETES, 2002, 51 (10) :2903-2910

← 1 2 3 4 5 6 7 8 9 →